The minimally important difference for the health assessment questionnaire in rheumatoid arthritis clinical practice is smaller than in randomized controlled trials

Journal of Rheumatology

Volumn 36, Issue 2, 2009, Pages 254-259

  Pope, Janet E ^a,d   Khanna, Dinesh ^b,c   Norrie, Deborah ^a   Ouimet, Janine M ^a  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d ST JOSEPH S HEALTH CENTRE   (Canada)

Author keywords

Health assessment questionnaire disability index; Minimally important difference; Randomized controlled trials; Rheumatoid arthritis

Indexed keywords

ADULT; ARTICLE; CLINICAL PRACTICE; CONTROLLED STUDY; DISEASE DURATION; DISEASE EXACERBATION; FEMALE; FOLLOW UP; HEALTH ASSESSMENT QUESTIONNAIRE; HEALTH STATUS; HUMAN; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PAIN; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; VISUAL ANALOG SCALE; ADOLESCENT; AGED; COMPARATIVE STUDY; DISABILITY; DISEASE COURSE; METHODOLOGY; MIDDLE AGED; OUTCOME ASSESSMENT; PAIN ASSESSMENT; PROSPECTIVE STUDY; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; REPRODUCIBILITY; STATISTICAL ANALYSIS; STATISTICS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ARTHRITIS, RHEUMATOID; DATA INTERPRETATION, STATISTICAL; DISABILITY EVALUATION; DISEASE PROGRESSION; FEMALE; HEALTH STATUS; HUMANS; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PAIN MEASUREMENT; PHYSICIAN'S PRACTICE PATTERNS; PROSPECTIVE STUDIES; QUESTIONNAIRES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REPRODUCIBILITY OF RESULTS; YOUNG ADULT;

EID: 64849101134     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: 10.3899/jrheum.080479     Document Type: Article

References (20)

1. Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum 1980;23:137-145 (Pubitemid 10164318)
2. Tugwell P, Wells G, Strand V, et al. Clinical improvement as reflected in measures of function and health-related quality of life following treatment with leflunomide compared with methotrexate in patients with rheumatoid arthritis: sensitivity and relative efficiency to detect a treatment effect in a twelve-month, placebo-controlled trial. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis Rheum 2000;43:506-514 (Pubitemid 30394940)
3. Wolfe F, Michaud K, Gefeller O, Choi HK. Predicting mortality in patients with rheumatoid arthritis. Arthritis Rheum 2003;48:1530-1542 (Pubitemid 36682360)
4. Sloane JA. Assessing the minimally clinically significant difference: scientific considerations, challenges and solutions. COPD 2005;2:57-62. (Pubitemid 40776224)
5. Kvien TK, Heiberg T, Hagen KB. Minimal clinically important improvement/difference (MCII/MCID) and patient acceptable symptom state (PASS): what do these concepts mean? Ann Rheum Dis 2007;66 Suppl:iii40-iii41.
6. Norman GR, Sloane JA, Wyrwich KW. Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation. Med Care 2003;41:582-592
7. Wells GA, Tugwell P, Kraag GR, Baker PR, Groh J, Redelmeier DA. Minimum important difference between patients with rheumatoid arthritis: the patient's perspective. J Rheumatol 1993;20:557-560 (Pubitemid 23102493)
8. Redelmeier DA, Lorig K. Assessing the clinical importance of symptomatic improvements. An illustration in rheumatology. Arch Intern Med 1993;153:1337-1342
9. Kosinski M, Zhao SZ, Dedhiya S, Osterhaus JT, Ware JE. Determining minimally important changes in generic and disease-specific health-related quality of life questionnaires in clinical trials of rheumatoid arthritis. Arthritis Rheum 2000;43:1478-1487 (Pubitemid 30452465)
10. Strand V, Tugwell P, Bombardier C, et al. Function and health-related quality of life: results from a randomized controlled trial of leflunomide versus methotrexate or placebo in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis Rheum 1999;42:1870-1878 (Pubitemid 30257751)
11. Strand V, Crawford B. Improvement in health-related quality of life in patients with SLE following sustained reductions in anti-dsDNA antibodies. Exp Rev Pharmacoeconomics Outcomes Res 2005;5:317-326 (Pubitemid 40894969)
12. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-324
13. Khanna D, Furst DE, Hays RD, et al. Minimally important difference in diffuse systemic sclerosis: results from the D-penicillamine study. Ann Rheum Dis 2006;65:1325-1329 Epub 2006 Mar 15. (Pubitemid 44620441)
14. Cohen J. A power primer. Psychol Bull 1992;112:155-159
15. Crosby RD, Kolotkin RL, Williams GR. Defining clinically meaningful change in health-related quality of life. J Clin Epidemiol 2003;56:395-407. (Pubitemid 36694091)
16. Wolfe F, Michaud K, Strand V. Expanding the definition of clinical differences: from minimally clinically important differences to really important differences. Analyses in 8931 patients with rheumatoid arthritis. J Rheumatol 2005;32:583-589 (Pubitemid 40524688)
17. Aletaha D, Smolen J, Ward MM. Measuring function in rheumatoid arthritis: Identifying reversible and irreversible components. Arthritis Rheum 2006;54:2784-2792 (Pubitemid 44497757)
18. Wyrwich KW. Minimal important difference thresholds and the standard error of measurement: is there a connection? J Biopharm Stat 2004;14:97-110.
19. Wyrwich KW, Tierney WM, Wolinsky FD. Further evidence supporting an SEM-based criterion for identifying meaningful intra-individual changes in health-related quality of life. J Clin Epidemiol 1999;52:861-873 (Pubitemid 29385600)
20. Wyrwich KW, Nienaber NA, Tierney WM, Wolinsky FD. Linking clinical relevance and statistical significance in evaluating intra-individual changes in health-related quality of life. Med Care 1999;37:469-478